pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 3 · small molecule · Achondroplasia
BMN 333 is a Phase 3 program evaluating vosoritide (brand name Voxzogo) for the treatment of achondroplasia, the most common form of genetic dwarfism. Vosoritide is a subcutaneous injection approved in Australia (May 2023), the European Union (November 2025), and the United States. The current Phase 2/3 trial (NCT 2025
Internal code 333-301
BMN 333 is a Phase 3 program evaluating vosoritide (brand name Voxzogo) for the treatment of achondroplasia, the most common form of genetic dwarfism. Vosoritide is a subcutaneous injection approved in Australia (May 2023), the European Union (November 2025), and the United States. The current Phase 2/3 trial (NCT 2025-523811-12-00) is a multicenter, randomized, operationally seamless study comparing BMN 333 versus vosoritide in children with achondroplasia, sponsored by BioMarin Pharmaceutical Australia Pty Ltd. Voxzogo is classified as a musculo-skeletal system therapeutic agent and is available in two formulations: 0.56 mg and 1.2 mg powder and solvent for solution for injection. The program represents BioMarin's ongoing clinical development strategy in rare genetic skeletal disorders, with regulatory approvals already established in major markets.
Achondroplasia affects approximately 1 in 25,000 live births and is characterized by severely restricted growth, with affected individuals typically reaching adult heights of 4 feet or less. The condition carries significant physical, psychological, and social morbidity throughout life. Prior to vosoritide's approval, no disease-modifying therapies were available; management was limited to supportive care and surgical interventions. The approval of Voxzogo represents the first pharmacological treatment to address the underlying pathophysiology of achondroplasia by modulating the fibroblast growth factor receptor (FGFR) signaling pathway. This addresses a substantial unmet medical need in a pediatric population with limited therapeutic options. Commercially, achondroplasia represents a niche but well-defined rare disease market with high treatment burden and strong patient advocacy. The competitive landscape includes other musculo-skeletal agents, though few directly target achondroplasia's molecular etiology. The Phase 2/3 trial comparing BMN 333 to vosoritide suggests potential optimization of dosing or formulation strategy, which could enhance clinical efficacy or safety profiles and strengthen market positioning in this orphan indication.
Drug Class: Musculo-skeletal system agent (ATC M05).
Modality: Small molecule.
Route of Administration: Subcutaneous injection.
Active Ingredient: Vosoritide (INN).
Brand Name: Voxzogo.
Formulations: 0.56 mg powder and solvent for solution for injection; 1.2 mg powder and solvent for solution for injection.
Mechanism of Action: Not yet disclosed in available facts.
Target: Not yet disclosed in available facts.
Related Therapies: Vosoritide is the first approved disease-modifying therapy for achondroplasia. Related agents in the musculo-skeletal space include other growth-modulating and bone metabolism agents, though direct mechanistic comparisons are not disclosed.
Also known as: ACH, achondroplastic dwarfism
Prevalence: Prevalence at birth: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Achondroplasia is the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
ClinicalTrials.gov lists 46 registered studies for Achondroplasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (16), PHASE3 (4), PHASE2/PHASE3 (3), PHASE1 (2), PHASE1/PHASE2 (1), PHASE4 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007037), Orphanet — achondroplasia, NCT00001536, NCT01435629, NCT01516229, NCT01541306, NCT01590446, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2/3 Trial Active
Multicenter, randomized, operationally seamless Phase 2/3 study evaluating BMN 333 versus vosoritide in children with achondroplasia (NCT 2025-523811-12-00) is ongoing.
Australian Approval
Voxzogo approved in Australia and listed on the ARTG with PBS codes 13270K, 13274P, 13275Q.
European Union Approval
Voxzogo approved by the European Medicines Agency (EMEA/H/C/005475).
United States Approval
Voxzogo approved by the FDA (NDA 214938); specific approval date not yet disclosed.
The competitive landscape for achondroplasia treatment includes several musculo-skeletal agents, though most are not specifically indicated for achondroplasia. Competitors identified in the facts include Ibandronic Acid Sandoz (Teva Pharma GmbH), Corora (Amgen), Aclasta (Apotex Pty Ltd), Crysvita (Kyowa Kirin Australia Pty Ltd), Osigraft, Evenity (Amgen), Osseor, Alendronic Acid/Colecalciferol Mylan, Vysribli (previously Denosumab Intas), Vantavo (previously Alendronate Sodium and Colecalciferol, MSD), Inductos, and Recombinant Human Growth Hormone (Xiyuan Hospital of China Academy of Chinese Medical Sciences). Most of these agents address bone metabolism, osteoporosis, or hypophosphatemia rather than achondroplasia specifically. Voxzogo's unique positioning as a disease-modifying therapy targeting the underlying pathophysiology of achondroplasia differentiates it from these competitors. The current Phase 2/3 trial comparing BMN 333 to vosoritide suggests BioMarin's strategy to optimize or differentiate its therapeutic approach within the achondroplasia space, potentially through dosing refinement or formulation enhancement.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Recombinant human growth hormone | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Approved |
| INFIGRATINIB | — | Fibroblast growth factor receptor inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Voxzogo approved; NDA 214938 filed with the FDA. Specific approval date not yet disclosed in available facts.
European Union: Voxzogo approved November 17, 2025 (EMEA/H/C/005475). Marketing Authorization Holder: BioMarin International Limited.
Australia: Voxzogo approved May 1, 2023. Listed on the Australian Register of Therapeutic Goods (ARTG) with PBS codes 13270K, 13274P, 13275Q. Sponsor: BioMarin Pharmaceutical Australia Pty Ltd.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Loss of Exclusivity: Expected loss-of-exclusivity date not yet disclosed.
Voxzogo (vosoritide) is used to treat achondroplasia, the most common form of genetic dwarfism, in children. It is the first disease-modifying therapy approved for this condition.
Yes. Voxzogo is approved in Australia (May 2023), the European Union (November 2025), and the United States. Specific US approval date is not yet disclosed.
BioMarin Pharmaceutical Australia Pty Ltd is the sponsor in Australia. BioMarin International Limited is the Marketing Authorization Holder in the European Union.
BMN 333 is in Phase 3 development. A multicenter, randomized, operationally seamless Phase 2/3 trial (NCT 2025-523811-12-00) comparing BMN 333 versus vosoritide in children with achondroplasia is currently active.
Voxzogo is administered as a subcutaneous injection. It is available in two formulations: 0.56 mg and 1.2 mg powder and solvent for solution for injection.
The specific mechanism of action is not yet disclosed in available facts.
The specific molecular target is not yet disclosed in available facts.
Achondroplasia is the most common form of genetic dwarfism, affecting approximately 1 in 25,000 live births. It is characterized by severely restricted growth and significant physical and psychological morbidity.
Specific pivotal trial details are not disclosed in available facts. The current Phase 2/3 trial (NCT 2025-523811-12-00) is comparing BMN 333 versus vosoritide in children with achondroplasia.
Voxzogo is classified as a musculo-skeletal system agent (ATC M05).
Voxzogo is the first disease-modifying therapy approved for achondroplasia. Other musculo-skeletal agents exist but are not specifically indicated for achondroplasia.
Voxzogo is listed on the Australian Register of Therapeutic Goods with PBS codes 13270K, 13274P, and 13275Q.
The EMA product number is EMEA/H/C/005475.
The FDA NDA number is NDA 214938.
BMN 333 is a small molecule therapeutic.
No partner or licensee information is disclosed in available facts.
333-301 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: The Phase 2/3 trial comparing BMN 333 to vosoritide suggests BioMarin is pursuing optimization of its achondroplasia therapeutic strategy. This could indicate efforts to improve dosing regimens, formulation characteristics, or clinical outcomes relative to the currently approved vosoritide standard. The operationally seamless design allows for potential protocol amendments based on interim data, indicating flexibility in trial execution.
Competitive Implications: Voxzogo's approvals in Australia, the EU, and the US establish BioMarin as the first-mover in disease-modifying therapy for achondroplasia. The current trial may be designed to support label expansions, dosing optimizations, or additional indications within the achondroplasia spectrum. No direct competitors with achondroplasia-specific approvals are evident from the facts provided, suggesting a relatively protected market position in this orphan indication.
Future Catalysts: Key milestones include completion and reporting of the Phase 2/3 trial data, potential regulatory submissions based on trial outcomes, and possible label expansions or dosing refinements. Geographic expansion into Japan and China would represent significant commercial opportunities given the global prevalence of achondroplasia.
Expected Milestones: Timing for Phase 2/3 trial completion, data readout, and subsequent regulatory actions are not yet disclosed. Peak sales projections and consensus analyst positions are not available in current facts.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.